Phosphorylation is a ubiquitous protein post-translational modification, and the importance of phosphorylation of serine, threonine and tyrosine is well established. What is lesser known is that almost all heteroatom-containing amino acids can be phosphorylated and, among these, histidine, aspartate and cysteine have well established roles in bacterial signalling pathways. The first of these, phosphohistidine, is the most unusual in that it is labile under many conditions used to study proteins in vitro and can exist as two different isomers. In the present short review, we highlight the chemical challenges that this modification presents and the manner in which chemical synthesis has been used to identify and mimic the modification in proteins.
Introduction
Almost every conceivable amino acid phosphorylation has been observed in Nature; this includes the phosphorylation of cysteine, of the acidic residues aspartate and glutamate, and of the basic residues histidine, lysine and arginine in addition to that of the most commonly observed hydroxy groups of serine, threonine and tyrosine. Phosphohistidine (pHis) is unique among these modifications in that phosphorylation can occur on either of the imidazole nitrogens, leading to two possible regioisomers (see Figure 2 ). These two isomers, telephosphohistidine (τ -pHis, 1), in which N1 is phosphorylated, and pros-phosphohistidine (π -pHis, 13), in which N3 is phosphorylated, are chemically and biochemically distinct. These are also sometimes referred to as 1-and 3-phosphohistidine respectively, although, strictly speaking, 1-phosphohistidine could refer to either isomer. In both isomers, the P-N bond is relatively high in energy; G 0 of hydrolysis is between − 50 and − 58 kJ·mol − 1 , significantly higher than that for phosphoesters (e.g. for phosphoserine, G 0 is between − 27 and − 40 kJ·mol − 1 ) [1] . Indeed, under acidic conditions (pH 1), whereas the phosphate esters (serine/threonine and tyrosine) have half-lives of several hours at 100
• C, both phosphohistidine regioisomers have half-lives of less than 1 min at 49
• C [2] . Under more physiological conditions, this pattern remains; whereas the phosphate esters are relatively stable, the phosphoramidate linkage in phosphohistidine is hydrolysed within hours [3] . The relative rates of hydrolysis of the two isomers suggests that τ -pHis (1) is the more stable isomer as under less acidic conditions (pH 5) it is hydrolysed ∼10-fold slower than π -pHis (13) . pHis is, however, stable under basic conditions in
Prevalence of phosphohistidine in prokaryotes and eukaryotes
Although making it challenging to observe and isolate, the high-energy nature of the phosphoramidate bond means that pHis is an excellent source of a phosphoryl group for other molecules and this is the context in which it has most commonly been observed. In bacteria, this lability is exploited in two-component signalling (Figure 1a) . A histidine residue on a sensor kinase is autophosphorylated as a result of a defined stimulus to generate a pHis residue, the phosphoryl group is then transferred to the cognate response regulator to generate a phosphoaspartate residue containing a high-energy phosphoanhydride [4] [5] [6] . This phosphorylated response regulator then elicits the biological response, usually by binding to DNA. A second ubiquitous system in bacteria using pHis is the sugar phosphotransferase system, via which bacteria regulate the import and catabolism of sugars using a cascade of phospho-transfer reactions (Figure 1a) . The system is primed by autophosphorylation of Enzyme I by PEP (phosphoenolpyruvate) to generate a τ -pHis residue [7] . The phosphoryl group is then transferred to the phosphocarrier protein HPr to generate a π -pHis residue [8] . Whereas these two intermediate species are common to the uptake of all sugars, the next transfer is to a sugar-specific Enzyme IIA. The phosphoryl group is then transferred to the imported sugar. The accumulation, or depletion, of specific phosphorylated intermediates then allows cross-regulation of sugar import leading to biphasic growth in a complex species-specific manner [9] .
Phosphohistidine also commonly occurs as an intermediate in phosphoryl group transfer enzymes such as phosphoglycerate mutases which alter the phosphorylation pattern of glycerate molecules [10] , NDPKs (nucleoside (3) to an aspartate residue in the cognate response regulator [6] leads to the desired response (4). In the sugar phosphotransfer system, a chain of phosphoryl transfer events forming both isomers of pHis leads from phosphoenolpyruvate via Enzyme I and HPr to phosphorylation of sugars entering the cell [7] [8] [9] . Accumulation of phosphorylated and unphosphorylated intermediates enables species-specific patterns of cross-regulation of sugar utilization. (b) Prototypical role of phosphohistidine as a catalytic intermediate in PPDK. A high-energy τ -pHis intermediate is formed in PPDK from ATP before transfer to pyruvate to form PEP [12] . In plants, this intermediate can be intercepted by an unusual ADP-dependent kinase which inactivates PPDK in a phosphohistidine-dependent manner [13] .
Figure 2 Examples of reported stable analogues of phosphohistidine
A wide variety of stable analogues of both τ -pHis (1) and π -pHis (13) have been reported including analogues based on a furan (2) [33] and pyrrole (3) [2] skeleton. Most recently, a range of analogues based on a triazole skeleton (4) have been independently reported by the groups of Piggott [32] , Muir [35] and Webb [36, 38] . Other recently reported analogues include the imidazole sulfonamide (5) reported by Eerland and Hedberg [40] and the alternative triazole (6) reported by Yang et al. [39] .
diphosphate kinases) in both prokaryotes and eukaryotes, which act to maintain cellular levels of NTPs [11] and PPDK (pyruvate o-phosphate dikinase) which is involved in the C 4 photosynthetic cycle and generates PEP from pyruvate [12] (Figure 1b) . The manner in which PPDK's activity is regulated is particularly remarkable; PDRP (pyruvate ophosphate dikinase regulatory protein) binds to PPDK in its histidine-phosphorylated form and transfers a phosphate group from ADP to a threonine residue proximal to the phosphohistidine [13] . The fact that PDRP requires a τ -pHis intermediate in PPDK for catalysis makes it an ideal model system with which to investigate histidine phosphorylation.
In eukaryotes, several other proteins have been identified as containing a phosphohistidine residue such as histone H4 [14] , heterotrimeric G-proteins [15] , succinyl-CoA synthetase [16] , annexin I [17] and P-selectin [18] . No system directly equivalent to either two-component signalling or the sugar-phosphotransferase system exists in eukaryotes; however, NDP kinase and its isoforms have been shown to be capable of transferring activated phosphoryl groups to histidine [19] and aspartate [20] residues in proteins.
Potential applications of stable analogues
The fundamental challenge in phosphohistidine research is that, at present, there is no straightforward robust methodology with which to detect histidine phosphorylation. Kee and Muir [21] have recently reviewed existing approaches to the detection of phosphohistidine including the use of MS approaches [21] . Such approaches have been widely used to analyse the modification in phospohistidinecontaining proteins after generation of the protein either by autophosphorylation [22, 23] or chemical phosphorylation [24, 25] . At present, however, no general pipeline for the identification of phosphohistidine by proteomic approaches has been described. A strategy to profile bacterial histidine kinases and their substrates using ATPγ S (adenosine 5 -[γ -thio]triphosphate) and the mesylate of p-nitrobenzyl alcohol was reported by Carlson et al. [26] . They demonstrated specific labelling of histidine residues and could also trace phosphotransfer from purified histidine kinases to cognate response regulators, but, once again, this approach has not yet been attempted in a more complex environment [26] .
For the majority of researchers, the most valuable tool for phosphohistidine research would be an antibody capable of identifying phosphohistidine in a sequenceindependent manner. Such monoclonal antibodies exist for phosphotyrosine; indeed, these antibodies have been shown to have a weak affinity for phosphohistidine [27] . Sequence-independent antibodies selective for many other modifications including lysine malonylation [28] have been described, but such antibodies do not exist for phosphoserine and phosphothreonine. Previous attempts using chemically generated pHis have been unsuccessful, and this is thought to be due to the in vivo rapid hydrolysis of the P-N bond [2] . An alternative strategy would therefore be to use a pHis analogue that suitably mimics the electrostatic surface of pHis to create such an antibody. Aside from development of a generic pHis antibody, pHis mimics could be used to enrich the level of pHis-binding proteins in cell lysates before identification by MS.
Phosphohistidine can be generated in vitro by treatment of proteins with potassium phosphoramidate [3] , and this procedure can be extended to generate peptides containing phosphohistidine [29] . This does not overcome the challenges associated with the lability of the modification and hydrolysis will still occur, although the rate of this can be limited by conducting experiments at high pH. The significantly more stable thiophosphohistidine can be generated using the analogous reaction with potassium thiophosphoramidate [30] ; this modification has been shown to be retained under acidic conditions (pH 1) for several hours [31] . However, attempts to use thiophosphohistidine as an immunogen to generate antibodies have not been successful and this has been attributed to hydrolysis of the thiophosphoryl group in vivo [32] .
Given the lability of pHis and its sulfur-containing analogues, the use of stable analogues is an attractive proposition. Two early approaches to this were analogues of τ -pHis (Figure 2a) : the phosphonofurylalanine analogue 2 generated by the group of Reymond [33] and the phosphonopyrrolylalanine analogue 3 generated by Attwood et al. [2] . In both cases, however, it was not possible to generate antibodies recognizing τ -pHis. Either the analogue did not elicit an immune response or the antibodies recognized the analogue, but not the modification. The synthesis of other structures which could conceivably be used in these applications such as the phosphonophenylalanine derivative [34] have also been reported, but these have not been used in antibody-generation experiments.
The most recent class of pHis analogue, phosphonotriazolylalanine, has, however, been shown to be effective in this application. The synthesis of this class was reported independently by three different groups including those of Muir [35] , Webb [36] and Piggott [32] . The first of these reports, that of Kee et al. [35] , reported the synthesis of peptides containing the 1,4-triazolylalanyl moiety (4) as an analogue of τ -pHis (1) and the 1,5-triazolylalanyl moiety (14) as an analogue of π -pHis (13) (Figure 2b ). Precursors for both peptides were generated by catalysed [3 + 2] cycloaddition of Boc (t-butoxycarbonyl)-protected azidoalanine to diethyl ethynylphosphonate [37] , catalysed by Cu(I) and Cp * Ru(COD)Cl (the latter acting on benzylprotected azidoalanine) to generate the precursors 7 and 15. Both could be used to generate peptides using the Boc strategy for SPPS (solid-phase peptide synthesis) and a peptide based on the sequence around His 18 in histone H4 was generated using this method. Subsequent cleavage of the peptide from the resin and deprotection using anhydrous HF yielded a peptide containing 4, which was used as the immunogen for antibody generation. This peptide was used to generate antibodies and, for the first time, the antibodies generated were shown to be able to recognize the mimicked modification in a defined sequence context.
Shortly afterwards, we reported our synthesis of the Fmocprotected derivative 8 and demonstrated that this could be used to generate peptides containing 4 using the Fmoc strategy for SPPS [36] . In this case, however, a two-step deprotection procedure using trimethylsilyl bromide was required to remove the ethyl esters from the phosphonate moiety. Although this has the advantage of making the synthesis of peptides containing 4 possible for those without access to an HF facility this was not an ideal scenario. Following on from this, Mukai et al. [32] reported the synthesis of analogues of τ -pHis (1) and π -pHis (13), using similar methodology. Taking a different approach, they produced compounds with either C-terminal methyl amides 11 and 17 or N-terminal acetamides 10 and 16.
Kee et al. [35] demonstrated that the triazole analogue of τ -pHis could be used to generate site-specific antibodies. We believed that generation of a triazole analogue precursor fully compatible with the Fmoc strategy would be essential for this approach to be generalized. We therefore chose to develop a precursor to 4 using benzyl protection for the phosphonate in place of ethyl protection [38] . Using P(III) chemistry (Figure 3a) , it was possible to develop a general strategy for incorporation of any desired protecting groups on the phosphonate and this strategy was used to produce the precursor 9. Standard conditions for peptide cleavage and deprotection are sufficient to remove the benzyl groups to yield peptides containing the triazole analogue. In our hands, this precursor has been used to generate a wide range of peptides containing 4 as an analogue of τ -pHis (1).
Subsequently, two further classes of analogues have been reported: a second class of triazole analogue and a distinct class of imidazolyl phosphonates. Yang et al. [39] used a triazole framework to generate the τ -pHis analogue 6; a peptide containing propargyl glycine was synthesized by Fmoc SPPS and subsequently reacted with 2-azidoethyl phosphonic acid to yield triazole-based analogue 6. Finally, Eerland and Hedberg [40] have reported the synthesis of imidazole sulfonamide (5). They proposed that this molecule would act as a transition-state analogue for phosphohistidine phosphatase activity [40] and might therefore be suitable as a pull-down probe for phosphohistidine phosphatases. A protected iodoimidazole sulfonamide building block was generated by ortholithiation and Negishi coupling then used to generate a protected 2-imidazolylalanine precursor (12) fully compatible with Fmoc SPPS (Figure 3b ).
Conclusion
In recent years, the development of stable analogues of phosphohistidine has provided a welcome new strategy for the detection of phosphohistidine in proteins. In combination with new strategies for MS analysis of the modification, this promises to allow biochemists to assess the function of known and suspected sites of histidine phosphorylation. Although the triazole pHis mimic (4) is already being used (a) Synthetic route to 9 [41] . P(III) chemistry is used to generate a dibenzyl-protected ethynyl phosphonate intermediate (22) which is then used to generate the precursor 9 via [3 + 2] cycloaddition. (b) Synthetic route to 12 [40] . Ortholithiation was used to iodinate a protected imidazole sulfonamide precursor (25) , allowing Negishi coupling to a protected iodoalanine moiety.
to investigate known pHis-binding proteins, the real leap forward in this field has yet to come. Although an antibody that can recognize phosphorylated histidine selectively over histidine has been produced, its sequence-dependence limits its application in a wider context; this may be because the triazole analogue (4) is not sufficiently similar to τ -pHis (1) to generate such an antibody. The electrostatic potential surface of the analogue suggests that the principal position at which the analogue will form hydrogen bonds [36] is N3 rather than N2. If a future generation of phosphohistidine analogues can more closely mimic the electrostatic potential of τ -pHis, then might these be used to generate a reagent capable of recognizing phosphohistidine in a sequenceindependent manner? Until such a day comes, however, recent developments mean that researchers in the field of histidine phosphorylation for the first time have tools that allow them to start to address the key challenges in histidine phosphorylation: where, how and why?
Note added in proof (received 31 May 2013)
Kee et al. [42] have recently reported the successful generation of an anti-pan-phosphohistidine antibody using a phosphonotriazoylylethylamine as a hapten together with its use in the detection of histidine phosphorylation on multiple proteins.
